Enbrel Biosimilar Market In Sandoz's Grasp; Will Cost, Litigation Derail It?
Executive Summary
With the FDA giving an overwhelmingly positive review of Sandoz Inc.'s application for its biosimilar version of Enbrel (etanercept), which is sold in the US by Amgen Inc., the product appears to be headed to the US market – pending a likely blessing from the agency's advisory panel, which is meeting on July 13. But Sandoz must still get past litigation and convince prescribers and patients its etanercept biosimilar provides value over Enbrel.
You may also be interested in...
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.
J&J Thinks It Can Win Over Biosimilar Competition
The big pharma reports strong 2Q earnings and executives talk about strategy for defending against biosimilar competition in the US.
J&J Thinks It Can Win Over Biosimilar Competition
The big pharma reports strong 2Q earnings and executives talk about strategy for defending against biosimilar competition in the US.